Panelists discuss how managed care organizations can improve Alzheimer diagnostic test access while navigating complex coverage challenges for amyloid-targeting therapies across traditional Medicare (with restrictive NCDs), Medicare Advantage plans, private insurance, and younger patients who face categorical exclusions despite clinical need.
Video content above is prompted by the following:
4. How can managed care organizations ensure that appropriate patients have access to diagnostic tests for Alzheimer disease?
5. What are some of the challenges with the current coverage landscape for amyloid-targeting therapies?
a. Expectation to discuss coverage for Medicare vs patients with Medicare Advantage vs private insurance plans as well as patients younger than 65 years.
Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO
May 2nd 2025To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.
Read More
Science at AACR Aims to Overcome Cancer Care Barriers
April 24th 2025A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
Read More